DK3222615T3 - Psma-bindende stoffer og anvendelser deraf - Google Patents
Psma-bindende stoffer og anvendelser deraf Download PDFInfo
- Publication number
- DK3222615T3 DK3222615T3 DK17167057.3T DK17167057T DK3222615T3 DK 3222615 T3 DK3222615 T3 DK 3222615T3 DK 17167057 T DK17167057 T DK 17167057T DK 3222615 T3 DK3222615 T3 DK 3222615T3
- Authority
- DK
- Denmark
- Prior art keywords
- binding substances
- psma binding
- psma
- substances
- binding
- Prior art date
Links
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 title 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 title 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 title 1
- 239000000126 substance Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
- C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/18—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/22—Tin compounds
- C07F7/2208—Compounds having tin linked only to carbon, hydrogen and/or halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nuclear Medicine (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8546208P | 2008-08-01 | 2008-08-01 | |
US11179108P | 2008-11-06 | 2008-11-06 | |
EP09803670.0A EP2318366B1 (en) | 2008-08-01 | 2009-07-31 | Psma-binding agents and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3222615T3 true DK3222615T3 (da) | 2022-06-20 |
Family
ID=41610978
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK17167057.3T DK3222615T3 (da) | 2008-08-01 | 2009-07-31 | Psma-bindende stoffer og anvendelser deraf |
DK09803670.0T DK2318366T3 (da) | 2008-08-01 | 2009-07-31 | Psma-bindende stoffer og anvendelser deraf |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK09803670.0T DK2318366T3 (da) | 2008-08-01 | 2009-07-31 | Psma-bindende stoffer og anvendelser deraf |
Country Status (22)
Country | Link |
---|---|
US (6) | US8778305B2 (da) |
EP (3) | EP4089074A1 (da) |
JP (6) | JP5588441B2 (da) |
KR (1) | KR101664855B1 (da) |
CN (3) | CN102171187B (da) |
AU (1) | AU2009276423B2 (da) |
CA (2) | CA2732632C (da) |
CY (2) | CY1119367T1 (da) |
DK (2) | DK3222615T3 (da) |
ES (2) | ES2914593T3 (da) |
FI (1) | FIC20230033I1 (da) |
HK (1) | HK1247197A1 (da) |
HR (2) | HRP20220742T1 (da) |
HU (3) | HUE059436T2 (da) |
LT (2) | LT2318366T (da) |
NL (1) | NL301250I2 (da) |
NO (1) | NO2024006I1 (da) |
PL (2) | PL3222615T3 (da) |
PT (2) | PT2318366T (da) |
RU (1) | RU2494096C2 (da) |
SI (2) | SI3222615T1 (da) |
WO (1) | WO2010014933A2 (da) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3656403B1 (en) | 2007-08-17 | 2022-05-11 | Purdue Research Foundation | Preparation process of psma binding ligand-linker conjugates |
WO2009070302A1 (en) * | 2007-11-30 | 2009-06-04 | The Johns Hopkins University | Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer |
USRE47609E1 (en) | 2007-12-28 | 2019-09-17 | Exini Diagnostics Ab | System for detecting bone cancer metastases |
EP4089074A1 (en) * | 2008-08-01 | 2022-11-16 | The Johns Hopkins University | Psma-binding agents and uses thereof |
AU2010249719A1 (en) | 2009-05-19 | 2012-05-31 | Aic Blab Company | Composite current collector and methods therefor |
US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US10011632B2 (en) | 2011-08-22 | 2018-07-03 | Siemens Medical Solutions Usa, Inc. | PSMA imaging agents |
US20130116404A1 (en) | 2011-11-08 | 2013-05-09 | Case Western Reserve University | Targeted non-invasive imaging probes of egfr expressing cells |
ES2941937T3 (es) * | 2011-11-30 | 2023-05-26 | Univ Johns Hopkins | Compuesto dirigido a PSMA y sus usos |
US20140065070A1 (en) * | 2012-08-28 | 2014-03-06 | Mcmaster University | Methods of preparing triazole-containing radioiodinated compounds |
JP6892218B2 (ja) * | 2012-11-15 | 2021-06-23 | エンドサイト・インコーポレイテッドEndocyte, Inc. | 薬物送達結合体およびpsma発現細胞によって引き起こされる疾患の治療方法 |
PT2970345T (pt) * | 2013-03-15 | 2019-09-06 | Cancer Targeted Tech Llc | Agentes de formação de imagem por tep sobre o amep marcado no 18f |
WO2015057692A1 (en) | 2013-10-14 | 2015-04-23 | The Johns Hopkins University | Prostate-specific membrane antigen-targeted photosensitizers for photodynamic therapy |
GEP20237496B (en) | 2013-10-18 | 2023-04-10 | Deutsches Krebsforsch | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
JP6292568B2 (ja) * | 2013-11-06 | 2018-03-14 | 国立大学法人京都大学 | ウレア誘導体化合物、これを含有する放射性医薬 |
US9713649B2 (en) | 2014-01-24 | 2017-07-25 | The Cleveland Clinic Foundation | PSMA-targeting imaging agents |
EP2993171A1 (en) * | 2014-09-04 | 2016-03-09 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for the production of 18F-labeled PSMA-specific PET-tracers |
EP3183236B1 (en) | 2014-08-24 | 2022-04-20 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften | Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer |
EP3011976A1 (en) * | 2014-10-20 | 2016-04-27 | Deutsches Krebsforschungszentrum | 18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents |
WO2016062370A1 (en) * | 2014-10-20 | 2016-04-28 | Deutsches Krebsforschungszentrum | 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
WO2016065145A2 (en) | 2014-10-22 | 2016-04-28 | The Johns Hopkins University | Psma targeted reversed carbamates and methods of use thereof |
US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
US20180338910A1 (en) * | 2015-01-09 | 2018-11-29 | The Johns Hopkins University | Intranasal administration of glutamate carboxypeptidase (gcp-ii) inhibitors |
US10869940B2 (en) | 2015-06-12 | 2020-12-22 | The Board Of Trustees Of The Leland Stanford Junior University | Targeted photoacoustic compounds, formulations, and uses thereof |
WO2017029399A1 (en) * | 2015-08-20 | 2017-02-23 | Universität Zu Köln | Pain tracking by pet-imaging (pain-trap) |
BR112018005899A2 (pt) | 2015-09-30 | 2018-10-16 | Deutsches Krebsforschungszentrum | composto e composição farmacêutica |
WO2017070482A2 (en) * | 2015-10-22 | 2017-04-27 | The Johns Hopkins University | Psma targeted radiohalogenated ureas for cancer radiotherapy |
KR101639599B1 (ko) | 2015-11-09 | 2016-07-14 | 서울대학교산학협력단 | 펩타이드 싸이오우레아 유도체, 이를 포함하는 방사성 동위원소 표지 화합물 및 이를 유효 성분으로 함유하는 전립선암 치료 또는 진단용 약학적 조성물 |
US10882871B2 (en) | 2016-01-10 | 2021-01-05 | British Columbia Cancer Agency Branch | 18/19F-labelled compounds which target the prostate specific membrane antigen |
JP7054390B2 (ja) * | 2016-06-10 | 2022-04-13 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 放射線標識した前立腺特異的膜抗原(PSMA)阻害剤 [18F]DCFPyL の改良合成 |
US10806806B2 (en) | 2016-06-23 | 2020-10-20 | Cornell University | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies |
CN117069621A (zh) * | 2016-06-23 | 2023-11-17 | 康奈尔大学 | 影响肿瘤杀伤的双重靶向构建体 |
US10340046B2 (en) | 2016-10-27 | 2019-07-02 | Progenics Pharmaceuticals, Inc. | Network for medical image analysis, decision support system, and related graphical user interface (GUI) applications |
WO2018090976A1 (zh) * | 2016-11-17 | 2018-05-24 | 思路迪(北京)医药科技有限公司 | 一种具有抗癌作用的化合物及其制备方法和应用 |
DE102016122273B4 (de) * | 2016-11-18 | 2018-06-21 | Abx Advanced Biochemical Compounds Gmbh | Präkursoren für die Radiofluorierung |
CN117563022A (zh) | 2017-04-05 | 2024-02-20 | 康奈尔大学 | 可用于成像和抗肿瘤治疗的具有可调的药代动力学的三功能构建体 |
WO2018187791A1 (en) | 2017-04-07 | 2018-10-11 | Juno Therapeutics, Inc | Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods |
WO2018204477A1 (en) | 2017-05-02 | 2018-11-08 | Cornell University | Methods and reagents for tumor targeting with greater efficacy and less toxicity |
ES2912392T3 (es) * | 2017-06-19 | 2022-05-25 | Futurechem Co Ltd | Compuesto marcado con 18F para el diagnóstico del cáncer de próstata y uso del mismo |
WO2018236115A1 (ko) | 2017-06-19 | 2018-12-27 | (주)퓨쳐켐 | 전립선암 진단을 위한 18f-표지된 화합물 및 그의 용도 |
CN116617420A (zh) | 2017-10-23 | 2023-08-22 | 约翰霍普金斯大学 | 靶向成纤维细胞活化蛋白α的化合物、药物组合物及用途 |
JP7317375B2 (ja) * | 2017-12-11 | 2023-07-31 | テクニシェ ユニバーシタット ミュンヘン | 画像化および内部放射線療法のためのpsmaリガンド |
AU2019205766A1 (en) | 2018-01-08 | 2020-06-18 | Exini Diagnostics Ab | Systems and methods for rapid neural network-based image segmentation and radiopharmaceutical uptake determination |
US10973486B2 (en) | 2018-01-08 | 2021-04-13 | Progenics Pharmaceuticals, Inc. | Systems and methods for rapid neural network-based image segmentation and radiopharmaceutical uptake determination |
MX2020008247A (es) | 2018-02-06 | 2021-02-26 | Univ Johns Hopkins | Urea-poliaminocarboxilatos radiohalogenados dirigidos a antígeno prostático específico de membrana (psma) para radioterapia de cáncer. |
WO2019183633A1 (en) | 2018-03-23 | 2019-09-26 | Case Western Reserve Univeristy | Psma targeted conjugate compounds and uses thereof |
CN109160898B (zh) * | 2018-05-16 | 2021-06-04 | 上海如絮生物科技有限公司 | 一种亲水性吡啶类化合物中间体及其制备方法 |
CN109160899B (zh) * | 2018-05-16 | 2021-06-04 | 上海如絮生物科技有限公司 | 一种亲水性吡啶类化合物、中间体、其制备方法及应用 |
CN109160896B (zh) * | 2018-05-16 | 2021-06-25 | 上海如絮生物科技有限公司 | 一种亲水性吡啶类化合物中间体及其制备方法 |
US20210338846A1 (en) * | 2018-07-30 | 2021-11-04 | The Johns Hopkins University | Competitive prostate-specific membrane antigen (psma) binding agents for reduction of non-target organ uptake of radiolabeled psma inhibitors for psma positive tumor imaging and radiopharmaceutical therapy |
CA3115806A1 (en) | 2018-10-11 | 2020-04-16 | Progenics Pharmaceuticals, Inc | Combination therapy for treating metastatic prostate cancer |
RU2697519C1 (ru) * | 2018-10-15 | 2019-08-15 | Общество с ограниченной ответственностью "Изварино Фарма" | Средство пептидной природы, включающее псма-связывающий лиганд на основе производного мочевины, способ его получения и применение для получения конъюгата с лекарственным и диагностическим агентом |
WO2020139012A1 (ko) | 2018-12-27 | 2020-07-02 | (주)퓨쳐켐 | 카르복시산이 도입된 psma-표적 화합물 및 그의 용도 |
JP2022516316A (ja) | 2019-01-07 | 2022-02-25 | エクシーニ ディアグノスティクス アーべー | プラットホーム非依存の全身画像セグメント化のためのシステムおよび方法 |
PL239934B1 (pl) * | 2019-04-12 | 2022-01-31 | Narodowe Centrum Badan Jadrowych Osrodek Radioizotopow Polatom | Pochodne inhibitorów PSMA do znakowania ⁹⁹ᵐTc poprzez HYNIC, zestaw radiofarmaceutyczny, preparat radiofarmaceutyczny oraz ich zastosowanie w diagnostyce raka prostaty |
JP2022530040A (ja) | 2019-04-24 | 2022-06-27 | プロジェニクス ファーマシューティカルズ, インコーポレイテッド | 核医学画像における強度ウィンドウ処理の双方向調節のためのシステムおよび方法 |
CA3136127A1 (en) | 2019-04-24 | 2020-10-29 | Progenics Pharmaceuticals, Inc. | Systems and methods for automated and interactive analysis of bone scan images for detection of metastases |
KR20220024595A (ko) | 2019-06-21 | 2022-03-03 | 프로빈셜 헬스 서비시즈 오쏘리티 | 전립선-특이적 막 항원을 표적으로 하는 방사성표지 화합물 |
RU2713151C1 (ru) * | 2019-07-02 | 2020-02-04 | Общество с ограниченной ответственностью "Изварино Фарма" | Конъюгат флуоресцентного красителя с веществом пептидной природы, включающим псма-связывающий лиганд на основе производного мочевины для визуализации клеток, экспрессирующих псма, способ его получения и применения |
CA3149598A1 (en) * | 2019-08-30 | 2021-03-04 | Naga Vara Kishore PILLARSETTY | Novel theranostic agents for psma positive cancers |
US11564621B2 (en) | 2019-09-27 | 2023-01-31 | Progenies Pharmacenticals, Inc. | Systems and methods for artificial intelligence-based image analysis for cancer assessment |
US11900597B2 (en) | 2019-09-27 | 2024-02-13 | Progenics Pharmaceuticals, Inc. | Systems and methods for artificial intelligence-based image analysis for cancer assessment |
US11544407B1 (en) | 2019-09-27 | 2023-01-03 | Progenics Pharmaceuticals, Inc. | Systems and methods for secure cloud-based medical image upload and processing |
US11321844B2 (en) | 2020-04-23 | 2022-05-03 | Exini Diagnostics Ab | Systems and methods for deep-learning-based segmentation of composite images |
US11386988B2 (en) | 2020-04-23 | 2022-07-12 | Exini Diagnostics Ab | Systems and methods for deep-learning-based segmentation of composite images |
CN111548305B (zh) * | 2020-05-12 | 2021-08-31 | 北京师范大学 | 一种可用于靶向psma的喹啉类化合物及其制备方法 |
EP4176377A1 (en) | 2020-07-06 | 2023-05-10 | Exini Diagnostics AB | Systems and methods for artificial intelligence-based image analysis for detection and characterization of lesions |
US11721428B2 (en) | 2020-07-06 | 2023-08-08 | Exini Diagnostics Ab | Systems and methods for artificial intelligence-based image analysis for detection and characterization of lesions |
WO2022101352A1 (en) | 2020-11-12 | 2022-05-19 | Abx Advanced Biochemical Compounds Gmbh | Ligands of prostate specific membrane antigen (psma) containing heteroaromatic linker building blocks |
CN114685599A (zh) * | 2020-12-30 | 2022-07-01 | 南京江原安迪科正电子研究发展有限公司 | 一种psma靶向抑制剂及放射性核素标记的psma靶向抑制剂、制备方法和用途 |
JPWO2023008556A1 (da) | 2021-07-30 | 2023-02-02 | ||
TW202324443A (zh) | 2021-10-08 | 2023-06-16 | 瑞典商艾西尼診斷公司 | 用於自動鑑別及分類局部淋巴及遠處轉移中之病變的系統和方法 |
WO2023239829A2 (en) | 2022-06-08 | 2023-12-14 | Progenics Pharmaceuticals, Inc. | Systems and methods for assessing disease burden and progression |
CN117670883B (zh) * | 2024-01-31 | 2024-05-07 | 中国医学科学院北京协和医院 | 一种鉴别高低级别膀胱癌的方法、设备和*** |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2233269C2 (ru) * | 1998-11-02 | 2004-07-27 | Авентис Фарма Лимитед | Замещенные анилиды, фармацевтическая композиция и способ лечения |
JP3750494B2 (ja) | 1999-08-31 | 2006-03-01 | 松下電器産業株式会社 | 半導体装置 |
WO2006093991A1 (en) * | 2005-03-02 | 2006-09-08 | The Cleveland Clinic Foundation | Compounds which bind psma and uses thereof |
PL3699162T3 (pl) * | 2006-11-08 | 2022-10-31 | Molecular Insight Pharmaceuticals, Inc. | Heterodimery kwasu glutaminowego |
EP2136788B1 (en) * | 2007-03-30 | 2011-10-26 | Bind Biosciences, Inc. | Cancer cell targeting using nanoparticles |
EP3466928A1 (en) * | 2007-06-26 | 2019-04-10 | The Johns Hopkins University | Labeled inhibitors of prostate-specific membrane antigen (psma), biological evaluation, and use as imaging agents |
EP4089074A1 (en) * | 2008-08-01 | 2022-11-16 | The Johns Hopkins University | Psma-binding agents and uses thereof |
GB0905438D0 (en) | 2009-03-30 | 2009-05-13 | Ge Healthcare Ltd | Radiolabelling reagents and methods |
JP7054390B2 (ja) * | 2016-06-10 | 2022-04-13 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 放射線標識した前立腺特異的膜抗原(PSMA)阻害剤 [18F]DCFPyL の改良合成 |
-
2009
- 2009-07-31 EP EP22163541.0A patent/EP4089074A1/en active Pending
- 2009-07-31 CA CA2732632A patent/CA2732632C/en active Active
- 2009-07-31 ES ES17167057T patent/ES2914593T3/es active Active
- 2009-07-31 DK DK17167057.3T patent/DK3222615T3/da active
- 2009-07-31 HU HUE17167057A patent/HUE059436T2/hu unknown
- 2009-07-31 JP JP2011521362A patent/JP5588441B2/ja active Active
- 2009-07-31 SI SI200932167T patent/SI3222615T1/sl unknown
- 2009-07-31 SI SI200931704T patent/SI2318366T1/sl unknown
- 2009-07-31 ES ES09803670.0T patent/ES2634894T3/es active Active
- 2009-07-31 EP EP17167057.3A patent/EP3222615B1/en active Active
- 2009-07-31 PT PT98036700T patent/PT2318366T/pt unknown
- 2009-07-31 CA CA2987744A patent/CA2987744C/en active Active
- 2009-07-31 PT PT171670573T patent/PT3222615T/pt unknown
- 2009-07-31 US US13/057,044 patent/US8778305B2/en active Active
- 2009-07-31 DK DK09803670.0T patent/DK2318366T3/da active
- 2009-07-31 LT LTEP09803670.0T patent/LT2318366T/lt unknown
- 2009-07-31 HU HUE09803670A patent/HUE034027T2/en unknown
- 2009-07-31 HR HRP20220742TT patent/HRP20220742T1/hr unknown
- 2009-07-31 AU AU2009276423A patent/AU2009276423B2/en active Active
- 2009-07-31 KR KR1020117004960A patent/KR101664855B1/ko active IP Right Grant
- 2009-07-31 CN CN200980139135.3A patent/CN102171187B/zh active Active
- 2009-07-31 PL PL17167057.3T patent/PL3222615T3/pl unknown
- 2009-07-31 RU RU2011107752/04A patent/RU2494096C2/ru active
- 2009-07-31 CN CN202110689899.2A patent/CN113563262A/zh active Pending
- 2009-07-31 LT LTEP17167057.3T patent/LT3222615T/lt unknown
- 2009-07-31 PL PL09803670T patent/PL2318366T3/pl unknown
- 2009-07-31 WO PCT/US2009/052456 patent/WO2010014933A2/en active Application Filing
- 2009-07-31 CN CN201710536671.3A patent/CN107382846B/zh active Active
- 2009-07-31 EP EP09803670.0A patent/EP2318366B1/en active Active
-
2012
- 2012-02-27 HK HK18106684.8A patent/HK1247197A1/zh unknown
-
2014
- 2014-03-14 US US14/211,683 patent/US9226981B2/en active Active
- 2014-07-25 JP JP2014152130A patent/JP5806765B2/ja active Active
-
2015
- 2015-09-04 JP JP2015174731A patent/JP6030724B2/ja active Active
-
2016
- 2016-01-04 US US14/987,032 patent/US9861713B2/en active Active
- 2016-10-20 JP JP2016206120A patent/JP6524046B2/ja active Active
-
2017
- 2017-07-21 HR HRP20171133TT patent/HRP20171133T1/hr unknown
- 2017-07-31 CY CY20171100825T patent/CY1119367T1/el unknown
-
2018
- 2018-01-08 US US15/864,236 patent/US10500292B2/en active Active
- 2018-11-26 JP JP2018220353A patent/JP7277113B2/ja active Active
-
2019
- 2019-11-05 US US16/674,089 patent/US20200282083A1/en not_active Abandoned
-
2021
- 2021-01-28 JP JP2021012046A patent/JP7219497B2/ja active Active
- 2021-04-22 US US17/237,850 patent/US20220088229A1/en active Pending
-
2023
- 2023-11-02 FI FIC20230033C patent/FIC20230033I1/fi unknown
- 2023-11-03 CY CY2023024C patent/CY2023024I1/el unknown
- 2023-11-14 HU HUS2300039C patent/HUS2300039I1/hu unknown
- 2023-11-15 NL NL301250C patent/NL301250I2/nl unknown
-
2024
- 2024-02-01 NO NO2024006C patent/NO2024006I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3222615T3 (da) | Psma-bindende stoffer og anvendelser deraf | |
DK2139490T3 (da) | Diazo-bicykliske smac-mimetiske stoffer og anvendelser deraf | |
DK2913344T3 (da) | Specifikke bindingsproteiner og anvendelser deraf | |
DK2170827T3 (da) | Indolin-2-oner og aza-indolin-2-oner | |
BRPI0907231A2 (pt) | pirrolpirimidinas e pirrolpiridinas | |
BRPI0815075A2 (pt) | Aglutinantes | |
DE602007010795D1 (de) | Blattsauger und -häcksler | |
BRPI0812509A2 (pt) | Aparelho reformador e método | |
DK3338790T3 (da) | Oligopeptid-forbindelser og anvendelser deraf | |
BRPI0820875A2 (pt) | Moléculas de ligação ao receptor de 0x40 | |
PL2256672T3 (pl) | Transponder i postać książki | |
BRPI0806964A2 (pt) | Combinações de agonístico beta-2-adrenoceptor e benzotiazolona | |
DK2328931T3 (da) | Selektive anti-hepcidin-25-antistoffer og anvendelser deraf | |
DK2160336T3 (da) | Forbindelsesmekanisme og fremgangsmåde | |
BRPI0921289A2 (pt) | Combinações pesticidas | |
DK2232089T3 (da) | Gevindindsats og køretøjskomponent | |
DE112009001577A5 (de) | Verstellpumpe | |
BRPI0907825A2 (pt) | Combinações pesticidas | |
DK2252688T3 (da) | Syntetiske phosphodiester-oligonukleotider og terapeutiske anvendelser deraf | |
DK2334596T3 (da) | Ferriphosphatbaseret sammensætning og anvendelse heraf | |
GB2462289B (en) | Book | |
NO20075424L (no) | Fremgangsmate og anvendelse | |
NO20073580L (no) | Penetrator | |
BRPI0815062A2 (pt) | Combinações pesticidas | |
DK2154144T3 (da) | Oligonukleotider og anvendelse deraf |